论文部分内容阅读
目的探讨腹膜透析(PD)患者并发心房颤动时抗凝治疗的重要性及安全性。方法选择2001年1月~2006年6月在我院接受PD治疗且并发心房颤动患者52例,分为A、B两组,A组不予以抗凝治疗,B组予以华法林口服治疗。对两组患者随访1年的血栓栓塞事件发生率及出血事件发生率进行对比分析。结果B组经抗凝治疗,其血栓栓塞事件发生率较A组明显下降,差异有统计学意义(P<0.01),两组出血事件发生率比较差异无统计学意义(P>0.05)。结论PD并发心房颤动患者进行华法林抗凝治疗对降低心房颤动所致血栓栓塞事件发生率有效且相对安全。
Objective To investigate the importance and safety of anticoagulant therapy in patients with peritoneal dialysis (PD) complicated with atrial fibrillation. Methods From January 2001 to June 2006 in our hospital for PD treatment and concurrent atrial fibrillation in 52 patients, divided into A, B two groups, A group was not anticoagulant therapy, B group was treated with warfarin. The incidence of thromboembolic events and the incidence of bleeding events in two groups were compared after one year of follow-up. Results The incidence of thromboembolism in group B was significantly lower than that in group A (P <0.01). There was no significant difference in the incidence of bleeding between the two groups (P> 0.05). Conclusions Warfarin anticoagulant therapy in patients with PD complicated with atrial fibrillation is effective and relatively safe in reducing the incidence of thromboembolic events caused by atrial fibrillation.